+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Treatment Market - Global Forecast to 2030- Product Image
Benign Prostatic Hyperplasia Treatment Market - Global Forecast to 2030- Product Image
Sale

Benign Prostatic Hyperplasia Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989822
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hyperplasia Treatment Market grew from USD 1.42 billion in 2024 to USD 1.50 billion in 2025. It is expected to continue growing at a CAGR of 5.91%, reaching USD 2.01 billion by 2030.

Benign prostatic hyperplasia (BPH) remains a prevalent urological condition affecting millions of men worldwide, characterized by progressive enlargement of the prostate gland and associated lower urinary tract symptoms. Innovations in pharmacotherapy, minimally invasive therapy and surgical intervention have significantly expanded treatment options, yet challenges persist in delivering personalized, cost-effective care. As the patient population ages, demand for therapies that balance efficacy, safety and quality of life intensifies. Healthcare providers and industry stakeholders must navigate shifting regulatory frameworks, evolving reimbursement models and increasing patient expectations for minimally disruptive procedures.

In this dynamic environment, a comprehensive understanding of market drivers, competitive forces and emerging technologies is critical for informed decision-making. This executive summary synthesizes key insights across transformative trends, regulatory influences, market segmentation, regional dynamics and competitive positioning. It culminates in strategic recommendations designed to guide pharmaceutical and medical device leaders toward sustainable growth and leadership in the BPH treatment arena.

Emerging Trends Reshaping the BPH Treatment Landscape

Over the past decade, the BPH treatment landscape has undergone a profound transformation driven by technological breakthroughs, shifts in clinical practice and patient preferences. Minimally invasive therapies such as water vapour ablation and prostate artery embolization are challenging traditional surgical gold standards by offering reduced recovery times and lower complication rates. Concurrently, digital health solutions and telemedicine platforms are enhancing patient monitoring, adherence tracking and remote consultation, thereby streamlining care pathways and improving outcomes.

Personalized medicine has emerged as another disruptive force; genetic profiling and biomarker research are paving the way for tailored drug regimens that optimize therapeutic response and minimize adverse effects. Artificial intelligence and machine learning tools now assist clinicians in risk stratification and treatment planning, supporting more precise intervention choices. Moreover, value-based healthcare models are reshaping reimbursement structures, incentivizing providers to adopt cost-efficient solutions that demonstrate clear clinical benefits. As these trends converge, traditional stakeholders must adapt their R&D pipelines, go-to-market strategies and partnership frameworks to stay competitive in an increasingly patient-centric market.

Analyzing the 2025 U.S. Tariffs and Their Impact on BPH Therapies

In 2025, the implementation of updated United States tariffs has introduced significant headwinds across the BPH treatment supply chain. Increased duties on medical device components, and on raw materials critical for producing catheters, electrodes and urology lasers, have elevated manufacturing costs. Pharmaceutical manufacturers, reliant on imported active pharmaceutical ingredients for alpha blockers and 5-alpha-reductase inhibitors, also face eroded margins, compelling many to reassess sourcing strategies.

These tariff pressures have spurred a shift toward regionalized supply networks and onshoring of key production processes. Companies are renegotiating supplier contracts, diversifying procurement channels and exploring additive manufacturing for specialized implants and stents to mitigate cost escalations. Meanwhile, healthcare providers are absorbing-or passing through-increased device and drug prices, potentially impacting patient access and adoption rates, particularly for cutting-edge minimally invasive therapies.

Despite these challenges, the industry has responded with innovative pricing models and strategic partnerships. Value-based agreements with payers, risk-sharing arrangements and bundled payment schemes are emerging as viable mechanisms to protect profitability while maintaining broad access to advanced BPH treatments.

Insights from Treatment Type, Product Type, and End User Segmentation

The BPH treatment market is distinctly segmented by treatment type, product type and end user, each segment exhibiting unique growth dynamics. Within treatment types, traditional medications-encompassing both alpha blockers and 5-alpha-reductase inhibitors-continue to anchor first-line therapy, yet minimally invasive approaches such as water vapour therapy and prostate artery embolization are rapidly gaining traction. Surgical solutions, spanning laser surgery, transurethral resection and incision of the prostate, alongside prostatic urethral lift procedures, are increasingly selected for patients with high symptom burden or pharmacotherapy intolerance.

In terms of product types, medical devices such as urology lasers and implants-including prostatic stents-are experiencing heightened demand driven by the rise of office-based interventions. Resectoscopes, electrodes and catheters remain fundamental but face margin pressure as competition intensifies. Among end users, ambulatory surgical centers are expanding their footprint for minimally invasive procedures, while clinics leverage telehealth integrations to manage long-term medication regimens. Hospitals maintain a dominant role for complex surgical cases but are under growing impetus to optimize resource utilization and reduce inpatient stays.

Integrating these segmentation perspectives reveals a market in flux, where shifting patient preferences and cost containment imperatives are driving convergence between pharmacological and device-based solutions. Companies that align product development and go-to-market strategies with these multi-dimensional segmentation insights will secure sustainable competitive advantages.

Regional Dynamics Influencing the Global BPH Treatment Market

Regional dynamics exert a powerful influence on BPH treatment adoption, reimbursement and regulatory pathways. In the Americas, mature healthcare infrastructure and well-established reimbursement frameworks have fueled early uptake of advanced laser surgery and office-based minimally invasive therapies. Patient awareness campaigns and urologist networks further support rapid commercialization of novel offerings.

Across Europe, Middle East & Africa, heterogeneous regulatory requirements and varied healthcare budgets create a mosaic of opportunity and challenge. Western European markets display high penetration of both pharmacological and laser-based interventions, whereas emerging EMEA regions prioritize cost-effective medications and are beginning to pilot water vapour and embolization techniques under pilot frameworks.

In Asia-Pacific, demographic trends-particularly a rapidly aging male population-combine with expanding healthcare access to drive robust growth. Countries such as Japan and South Korea lead in adopting cutting-edge minimally invasive therapies, while markets in China and India are focused on improving affordability through domestic manufacturing and generic formulations. The interplay between developed and emerging regional forces underscores the need for differentiated market entry and commercialization strategies tailored to local regulatory and reimbursement landscapes.

Competitive Landscape: Leading Companies in BPH Treatment

The competitive landscape features an array of established pharmaceutical and medical device players deploying diverse strategies to capture market share. Abbott Laboratories and AbbVie Inc. are leveraging their pharmaceutical heritage to advance combination regimens that address multifactorial symptom profiles. Bayer AG, Merck & Co., Inc. and Sanofi S.A. continue to optimize their portfolios of alpha blockers and enzyme inhibitors through lifecycle management and next-generation formulation development.

On the device front, Boston Scientific Corporation, Olympus Corporation and Lumenis Ltd. are reinvesting in research for enhanced urology lasers and navigated prostatic stent systems. Medtronic PLC and Teleflex Incorporated are focusing on ergonomic catheter designs and novel electrode technologies to streamline clinic-based interventions. Concurrently, market entrants such as Dr. Reddy’s Laboratories, Lupin Pharmaceuticals and Sun Pharmaceutical Industries Ltd. are intensifying competition in generics and biosimilars, driving price pressures across established drug classes.

Strategic alliances and mergers-illustrated by partnerships between Asahi Kasei Corporation and Astellas Pharma Inc.-are reshaping the value chain, enabling cross-border research, shared manufacturing and co-development of integrated drug-device combinations. Companies that excel in forging agile collaborations and aligning their pipelines with evolving clinical guidelines will emerge as the clear leaders in the BPH treatment arena.

Strategic Recommendations for Stakeholders in BPH Treatment

Industry leaders must pursue a multi-pronged approach to capitalize on emerging opportunities and mitigate headwinds. First, accelerating R&D in minimally invasive therapies and combination pharmacotherapies will address growing demand for personalized, patient-centric solutions. Second, adopting advanced manufacturing-such as localized production of key device components-can shield margins from tariff volatility and supply chain disruptions.

Third, forging collaborative partnerships with digital health providers will enhance patient engagement, remote monitoring and adherence management, reinforcing the value proposition of both pharmaceuticals and devices. Fourth, exploring value-based contracting with payers and deploying outcome-focused pricing models will ensure sustainable reimbursement while demonstrating clear clinical benefit. Finally, tailoring market entry strategies to specific regional dynamics-acknowledging differences in regulatory requirements, healthcare infrastructure and cost sensitivities-will be critical for maximizing adoption and market penetration.

Conclusion: Positioning for Future Success in BPH Treatment

The evolving landscape of BPH treatment presents both formidable challenges and exciting opportunities. Innovations in minimally invasive therapies, personalized pharmacology and digital health integration are redefining standards of care, while regulatory and tariff pressures necessitate agile supply chain and pricing strategies. By synthesizing segmentation insights, regional dynamics and competitive intelligence, stakeholders can make informed decisions that drive growth and improve patient outcomes.

Moving forward, a balanced portfolio approach-encompassing drug, device and digital solutions-will enable companies to address diverse patient needs and capture value across the care continuum. Strategic partnerships, investment in local manufacturing and commitment to value-based agreements will further differentiate leading organizations, positioning them to thrive amid shifting market forces.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Medications
    • 5-Alpha-Reductase Inhibitors
    • Alpha Blockers
  • Minimally Invasive Therapies
    • Prostate Artery Embolization
    • Water Vapour Therapy
  • Surgical Treatments
    • Laser Surgery
    • Prostatic Urethral Lift
    • Transurethral Incision Of The Prostate
    • Transurethral Resection Of The Prostate
  • Catheters
  • Electrodes
  • Implants
  • Prostatic Stents
  • Resectoscopes
  • Urology Laser
  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lumenis Ltd.
  • Lupin Pharmaceuticals
  • Medtronic PLC
  • Merck & Co., Inc.
  • Merit Medical Systems
  • Mylan N.V.
  • Olympus Corporation
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type
8.1. Introduction
8.2. Medications
8.2.1. 5-Alpha-Reductase Inhibitors
8.2.2. Alpha Blockers
8.3. Minimally Invasive Therapies
8.3.1. Prostate Artery Embolization
8.3.2. Water Vapour Therapy
8.4. Surgical Treatments
8.4.1. Laser Surgery
8.4.2. Prostatic Urethral Lift
8.4.3. Transurethral Incision Of The Prostate
8.4.4. Transurethral Resection Of The Prostate
9. Benign Prostatic Hyperplasia Treatment Market, by Product Type
9.1. Introduction
9.2. Catheters
9.3. Electrodes
9.4. Implants
9.5. Prostatic Stents
9.6. Resectoscopes
9.7. Urology Laser
10. Benign Prostatic Hyperplasia Treatment Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Hospitals
11. Americas Benign Prostatic Hyperplasia Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Abbott Laboratories
14.3.2. AbbVie Inc.
14.3.3. Asahi Kasei Corporation
14.3.4. Astellas Pharma Inc.
14.3.5. Bayer AG
14.3.6. Boehringer Ingelheim GmbH
14.3.7. Boston Scientific Corporation
14.3.8. Cipla Ltd.
14.3.9. Dr. Reddy’s Laboratories
14.3.10. Eli Lilly and Company
14.3.11. Endo International PLC
14.3.12. GlaxoSmithKline plc
14.3.13. Hikma Pharmaceuticals PLC
14.3.14. Lumenis Ltd.
14.3.15. Lupin Pharmaceuticals
14.3.16. Medtronic PLC
14.3.17. Merck & Co., Inc.
14.3.18. Merit Medical Systems
14.3.19. Mylan N.V.
14.3.20. Olympus Corporation
14.3.21. Pfizer, Inc.
14.3.22. Sanofi S.A.
14.3.23. Sun Pharmaceutical Industries Ltd.
14.3.24. Teleflex Incorporated
14.3.25. Teva Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 53. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 54. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 85. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 86. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 87. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 91. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 92. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 93. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 194. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 195. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 196. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 218. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 220. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 224. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 225. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lumenis Ltd.
  • Lupin Pharmaceuticals
  • Medtronic PLC
  • Merck & Co., Inc.
  • Merit Medical Systems
  • Mylan N.V.
  • Olympus Corporation
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 151 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
2025 Global Forecast for Benign Prostatic Hyperplasia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Benign Prostatic Hyperplasia Treatment Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Benign Prostatic Hyperplasia Drug Market

Benign Prostatic Hyperplasia (BPH) is a condition that affects the prostate gland in men. It is characterized by an enlarged prostate, which can cause urinary symptoms such as difficulty starting or stopping the flow of urine, a weak or interrupted urine stream, and a feeling of incomplete bladder emptying. BPH is not cancerous, but it can lead to an increased risk of developing prostate cancer. The BPH drug market is composed of a variety of medications used to treat the symptoms of BPH. These medications include alpha-blockers, 5-alpha reductase inhibitors, and anticholinergics. Alpha-blockers work by relaxing the muscles of the bladder neck and prostate, allowing for improved urine flow. 5-alpha reductase inhibitors reduce the size of the prostate, while anticholinergics reduce bladder contractions. The BPH drug market is a subset of the larger prostate cancer drug market. Prostate cancer drugs are used to treat prostate cancer, which is the second most common cancer in men. These drugs include hormone therapy, chemotherapy, and immunotherapy. Some companies in the BPH drug market include Allergan, Astellas Pharma, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.